Abstract
The gold standard for the treatment of pure aortic insufficiency (PAI) is surgical valve repair or replacement. With the newest transcatheter heart valve technologies and the accumulating years of experience of heart teams with the current transcatheter aortic valve replacement (TAVR) prostheses, implanters have pushed the envelope with off-label use of those valves designed and approved for aortic stenosis, in patients with PAI especially those at higher risks or for compassionate use. However, new prostheses are currently under investigation in clinical use and evidence is provided on the safety and efficacy of those latter. Will be discussed in this commentary, the actual clinical evidence and the use of transcatheter heart valves, in- and off-label, for the treatment of PAI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
